Esta página se tradujo automáticamente y no se garantiza la precisión de la traducción. por favor refiérase a versión inglesa para un texto fuente.

ASsessing The REAl-world Safety & Effectiveness of Spinal Muscular Atrophy Participants Treated With Intrathecal Onasemnogene Abeparvovec-brve (OAV101B) (ITVISMA®): A U.S. Pragmatic Multicenter Study (STREAM)

28 de octubre de 2026 actualizado por: Novartis Pharmaceuticals

Onasemnogene Abeparvovec: Evaluación de la Seguridad y Efectividad en el Mundo Real de Participantes con Atrofia Muscular Espinal Tratados con Onasemnogene Abeparvovec-brve Intratecal (ITVISMA®): Un Estudio Multicéntrico Pragmático en EE.UU. (STREAM)

The primary purpose is to address critical evidence in the treatment landscape for Spinal Muscular Atrophy (SMA), specifically focusing on the intrathecal formulation of onasemnogene abeparvovec-brve (ITVISMA®). U.S. Pragmatic Multicenter Study (STREAM).

Descripción general del estudio

Estado

Reclutamiento

Intervención / Tratamiento

Descripción detallada

STREAM is a prospective, multicentre cohort study that will follow U.S. participants with genetically confirmed SMA who receive a single, intrathecal dose of onasemnogene abeparvovec-brve. All eligible participants are enrolled prior to therapeutic injection. No randomisation, blinding, or placebo control is employed; instead, each participant acts as his or her own baseline comparator. This study will use an exploratory external cohort of patients matched by age, clinical characteristics, treatment history and availability of at least 1 year of pre-treatment medical history. This patient cohort will be based on a database of retrospectively collected electronic medical records data and will be used descriptively to contextualize study outcomes. Bias is minimised through pre-specified endpoints, uniform rater training on motor-function scales, and a detailed statistical analysis plan that stipulates handling of missing data and intercurrent events in advance.

Tipo de estudio

Intervencionista

Inscripción (Estimado)

36

Fase

  • Fase 4

Contactos y Ubicaciones

Esta sección proporciona los datos de contacto de quienes realizan el estudio e información sobre dónde se lleva a cabo este estudio.

Estudio Contacto

Copia de seguridad de contactos de estudio

  • Nombre: Novartis Pharmaceuticals

Ubicaciones de estudio

    • Arkansas
      • Little Rock, Arkansas, Estados Unidos, 208833
        • Reclutamiento
        • Arkansas Children's Hospital
        • Investigador principal:
          • Aravindhan Veerapandiyan
        • Contacto:
          • Buffy Gofforth
          • Número de teléfono: (501) 364-1591
    • California
      • Stanford, California, Estados Unidos, 94305-5235
        • Reclutamiento
        • Stanford Hospital
        • Contacto:
        • Investigador principal:
          • John W Day
    • Massachusetts
      • Boston, Massachusetts, Estados Unidos, 02215
        • Reclutamiento
        • Boston Childrens Hospital
        • Contacto:
        • Investigador principal:
          • Leslie Hayes
    • New York
      • New York, New York, Estados Unidos, 10032
        • Reclutamiento
        • Columbia University Medical Center
        • Investigador principal:
          • Claudia Chiriboga
        • Contacto:
    • Ohio
      • Columbus, Ohio, Estados Unidos, 43210
        • Reclutamiento
        • Ohio State University Medical Center
        • Investigador principal:
          • Bakri Elsheikh
        • Contacto:
    • Pennsylvania
      • Philadelphia, Pennsylvania, Estados Unidos, 209277
        • Reclutamiento
        • University of Pennsylvania
        • Investigador principal:
          • Lauren Elman
        • Contacto:

Criterios de participación

Los investigadores buscan personas que se ajusten a una determinada descripción, denominada criterio de elegibilidad. Algunos ejemplos de estos criterios son el estado de salud general de una persona o tratamientos previos.

Criterio de elegibilidad

Edades elegibles para estudiar

2 años a 100 años (Niño, Adulto, Adulto Mayor)

Acepta Voluntarios Saludables

No

Géneros elegibles para el estudio

Todos

Descripción

Key Inclusion Criteria:

A participant will be enrolled in STREAM only if all the following conditions are met:

  • The participant has a genetically confirmed diagnosis of SMA (biallelic SMN1 deletion or mutation).

  • He or she is ≥ 2 years of age on the day of the intrathecal injection.

  • The treating Investigator intends to administer within the current episode of care, a single dose of ITVISMA® (1.2 × 10¹⁴ vg) in routine U.S. practice after written informed consent obtained.

  • One of the following functional categories applies at screening:

    1. independently ambulatory child/adolescent 2 - <18 years; or
    2. independently ambulatory adult (≥ 18 years).
    3. non-ambulatory (includes walkers with assistance) adult > 18 years with entry level RULM at baseline
  • At least 1 year of pre-treatment medical history, including motor-function documentation, can be retrieved from the site electronic record.

Key Exclusion Criteria:

A participant will be excluded if any of the following conditions apply:

  • Contraindication for lumbar puncture as determined by the investigator (e.g., spinal anatomy that precludes safe lumbar puncture)
  • An uncontrolled acute illness, active infection, febrile illness or acute medical condition, within 30 days prior to dosing
  • Inability to tolerate corticosteroids administered by mouth or gastrostomy tube
  • Current participation in another interventional clinical trial that would interfere with the objectives or endpoints of STREAM. Note: participation in observational cohort studies or non-interventional studies in which the participant does not receive treatment or undergo procedures which may compromise this study data integrity may be allowed following Sponsor approval
  • Planned relocation or any circumstance that is likely to prevent completion of the minimum 12-month follow-up.

Other protocol inclusion, exclusion criteria may apply.

Plan de estudios

Esta sección proporciona detalles del plan de estudio, incluido cómo está diseñado el estudio y qué mide el estudio.

¿Cómo está diseñado el estudio?

Detalles de diseño

  • Propósito principal: Tratamiento
  • Asignación: N / A
  • Modelo Intervencionista: Asignación de un solo grupo
  • Enmascaramiento: Ninguno (etiqueta abierta)

Armas e Intervenciones

Grupo de participantes/brazo
Intervención / Tratamiento
Experimental: Onasemnogene Abeparvovec-brve

Participants with spinal muscular atrophy, including:

  • independently ambulatory children/adolescents (≥ 2 years to < 18 years);
  • independently ambulatory adults (≥ 18 years);
  • Non-ambulatory adults (≥ 18 years)

administered once via lumbar puncture with systemic corticosteroid prophylaxis per label.

Otros nombres:
  • (ITVISMA®)

¿Qué mide el estudio?

Medidas de resultado primarias

Medida de resultado
Medida Descripción
Periodo de tiempo
Change from baseline in HFMSE for independently ambulatory participants
Periodo de tiempo: Baseline, 6, 12, 18 and 24 months

The HFMSE is a validated SMA specific assessment devised for use in children with SMA to give objective information on motor ability and clinical progression.

The HFMSE contains 33 items rated from 0 (unable to perform) to 2 (performs without modification/adaptation/compensation). Total scores range from 0-66. Higher scores indicate higher levels of motor ability.

Baseline, 6, 12, 18 and 24 months
Change from baseline in RULM for non-ambulatory (including walkers with assistance) participants
Periodo de tiempo: Baseline, 6, 12, 18 and 24 months

The RULM is a validated SMA specific assessment of motor performance in the upper limbs from childhood through adulthood in independent ambulatory and non-ambulatory (including walkers with assistance) individuals with SMA. The scale consists of 19 scorable items: 18 items scored on 0 (unable) to 2 (full achievement) scale, and one item that is scored from 0 (unable) to 1 (able). Total scores range from 0-37 points. Higher scores reflect higher level of motor ability.

Baseline, 6, 12, 18 and 24 months

Medidas de resultado secundarias

Medida de resultado
Medida Descripción
Periodo de tiempo
Incidence of Adverse Events (AEs) and Serious Adverse Events (SAEs)
Periodo de tiempo: up to 5 years

Incidence of AEs and SAEs, including changes in laboratory tests and procedure-related events qualifying and reported as AEs.

up to 5 years
Modified SMA Functional Rating Scale (SMA-FRS) for independently ambulatory participants (≥ 18 years of age) and non-ambulatory particpants
Periodo de tiempo: Baseline, 6, 12, 18 and 24 months and Years 3, 4, and 5

Modified Spinal Muscular Atrophy Functional Rating Scale (SMAFRS): Ten items address questions related to eating, upper extremity dressing, lower extremity dressing, grooming, bathing, toileting, turning in bed and adjusting bed clothes, transfers, walking, and climbing stairs. This outcome measure includes effectiveness assessment across predefined participant groups based on relevant clinical and demographic factors, as specified in the protocol.

Baseline, 6, 12, 18 and 24 months and Years 3, 4, and 5
Assessment of Caregiver Experience with Neuromuscular Disease (ACEND) for independently ambulatory participants (<18 years of age)
Periodo de tiempo: Baseline, Months 6, 12, 18, 24, and Years 3, 4, and 5

The Assessment of Caregiver Experience with Neuromuscular Disease (ACEND): quantifies caregivers' perceptions of function and quality of life pertaining to time, finance and emotion. The ACEND was developed and validated to specifically assess caregiver impact experienced by raising children severely affected by neuromuscular diseases. While specifically developed for application to caregivers of patients undergoing orthopedic surgery, it has application to those with SMA. This outcome measure includes effectiveness assessment across predefined participant groups based on relevant clinical and demographic factors, as specified in the protocol.

Baseline, Months 6, 12, 18, 24, and Years 3, 4, and 5
Subgroup outcomes: Hammersmith Functional Motor Scale Expanded (HFMSE)
Periodo de tiempo: Baseline, 6, 12, 18 and 24 months

Effectiveness assessment across predefined participant groups based on relevant clinical and demographic factors, as specified in the protocol. The HFMSE is a validated SMA specific assessment to give objective information on motor ability and clinical progression. Total scores range from 0-66. Higher scores indicate higher levels of motor ability.

Baseline, 6, 12, 18 and 24 months
Subgroup outcomes: Revised Upper Limb Module (RULM)
Periodo de tiempo: Baseline, 6, 12, 18 and 24 months

Effectiveness assessment across predefined participant groups based on relevant clinical and demographic factors, as specified in the protocol. The RULM is a validated SMA specific assessment of motor performance in the upper limbs from childhood through adulthood in independent ambulatory and non-independent ambulatory individuals with SMA. Total scores range from 0-37 points. Higher scores reflect higher level of motor ability.

Baseline, 6, 12, 18 and 24 months
Frequency of hospitalizations emergency department visits, outpatient visits, respiratory interventions and nutritional support interventions
Periodo de tiempo: Baseline, Months 6, 12, 18, 24, and Years 3, 4, and 5

Assessment of SMA-related healthcare-resource utilisation.

Baseline, Months 6, 12, 18, 24, and Years 3, 4, and 5
Duration of hospitalizations emergency department visits, outpatient visits, respiratory interventions and nutritional support interventions
Periodo de tiempo: Baseline, Months 6, 12, 18, 24, and Years 3, 4, and 5

Assessment of SMA-related healthcare-resource utilisation.

Baseline, Months 6, 12, 18, 24, and Years 3, 4, and 5
Cobb angle
Periodo de tiempo: Baseline, up to 24 months

Assessment of scoliosis progression as a disease-progression marker.

Baseline, up to 24 months
Daily hours of respiratory support (none, non-invasive ventilation, invasive ventilation)
Periodo de tiempo: Baseline, up to 24 months

Assessment of respiratory function as a disease-progression marker.

Baseline, up to 24 months
Joint-range limitation measured by goniometer
Periodo de tiempo: Baseline, up to 24 months

Assessment of evolution of joint contractures as a disease-progression marker.

Baseline, up to 24 months
Nutritional-support category (oral, gastrostomy feeds, total parenteral nutrition)
Periodo de tiempo: Baseline, up to 24 months

Assessment of nutrition status as a disease-progression marker.

Baseline, up to 24 months
6-Minute Walk Test (6MWT) for ambulatory patients
Periodo de tiempo: Baseline, Months 6, 12, 18, and 24

To assess disease-progression markers. 6MWT: distance in metres; greater distance indicates better ambulatory capacity.

Baseline, Months 6, 12, 18, and 24

Colaboradores e Investigadores

Aquí es donde encontrará personas y organizaciones involucradas en este estudio.

Fechas de registro del estudio

Estas fechas rastrean el progreso del registro del estudio y los envíos de resultados resumidos a ClinicalTrials.gov. Los registros del estudio y los resultados informados son revisados ​​por la Biblioteca Nacional de Medicina (NLM) para asegurarse de que cumplan con los estándares de control de calidad específicos antes de publicarlos en el sitio web público.

Fechas importantes del estudio

Inicio del estudio (Actual)

27 de agosto de 2026

Finalización primaria (Estimado)

3 de mayo de 2032

Finalización del estudio (Estimado)

30 de junio de 2032

Fechas de registro del estudio

Enviado por primera vez

26 de febrero de 2026

Primero enviado que cumplió con los criterios de control de calidad

26 de febrero de 2026

Publicado por primera vez (Actual)

4 de marzo de 2026

Actualizaciones de registros de estudio

Última actualización publicada (Actual)

29 de octubre de 2026

Última actualización enviada que cumplió con los criterios de control de calidad

28 de octubre de 2026

Última verificación

1 de octubre de 2026

Más información

Términos relacionados con este estudio

Plan de datos de participantes individuales (IPD)

¿Planea compartir datos de participantes individuales (IPD)?

SÍ

Descripción del plan IPD

Novartis is committed to sharing with qualified external researchers, access to patient-level data and supporting clinical documents from eligible studies. These requests are reviewed and approved by an independent review panel on the basis of scientific merit. All data provided is anonymized to respect the privacy of patients who have participated in the trial in line with applicable laws and regulations. This trial data availability is according to the criteria and process described on www.clinicalstudydatarequest.com.

Información sobre medicamentos y dispositivos, documentos del estudio

Estudia un producto farmacéutico regulado por la FDA de EE. UU.

Sí

Estudia un producto de dispositivo regulado por la FDA de EE. UU.

No

Esta información se obtuvo directamente del sitio web clinicaltrials.gov sin cambios. Si tiene alguna solicitud para cambiar, eliminar o actualizar los detalles de su estudio, comuníquese con register@clinicaltrials.gov. Tan pronto como se implemente un cambio en clinicaltrials.gov, también se actualizará automáticamente en nuestro sitio web. .

Suscribir